19-Oct-2026 14:20:23
NATCOPHARMGeneral news
NATCO : LAUNCHES CARBOPLATIN INJECTION IN US MARKET
• U.S. subsidiary NATCO Pharma USA LLC launches generic version of Paraplatin • Launch in manufacturing collaboration with Chennai-based Teyro Labs Pvt Ltd • Product indicated for advanced ovarian carcinoma, including first-line combination and palliative treatment • Company says launch helps address a critical shortage of the product in the U.S. market • Carboplatin Injection had estimated U.S. sales of USD 27.8 million for 12 months ending June'26
Natco Pharma Limited
Open attachment